Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilar is expanding its footprints worldwide with multiple collaborations. In Jan 2020, Pfizer launched its two biosimilars [Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab)] at lowest WAC in the USOur team at PharmaShots has summarized key…